Final Frontier in LUTS; Targeting the Urothelium to Treat OAB, IC/BPS, Hypersensitive Bladder and Ketamine Cystitis

Workshop 19

Workshop Schedule

09:00

Hann-Chorng Kuo

09:05

Lori Birder

09:35

Yao-Chi Chuang

10:00

Hann-Chorng Kuo

10:30

None

11:00

Michael Chancellor

11:20

Yao-Chi Chuang

11:35

Chun-Hou Liao

11:55

All

Aims & Objectives

Advanced
180 minutes
Detrusor Overactivity
Urothelium Botulinum toxin Liposome
Urologists, urogynecologists, clinical and basic researchers
Urothelial dysfunction might play a role in the abnormality of expression of sensory receptors or release of transmitters in the suburothelial nerves or interstitial cells. In this regard, intravesical treatment to inhibit receptor expression or transmitter release might provide good therapeutic effects in the treatment of sensory urgency, interstitial cystitis/bladder pain syndrome, and overactive bladder (OAB). Intravesical pharmacotherapy has been used for the treatment of refractory OAB and IC/BPS, however, an important obstacle in the success of intravesical drug delivery arises from the low permeability of bladder epithelium. This workshop helps participants select suitable intravesical treatment for urothelial associated LUTD.